Integration of panitumumab into the treatment of colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 1, 2010, Pages 16-26

  Gravalos, Cristina ^a   Cassinello, Javier ^b   García Alfonso, Pilar ^c   Jimeno, Antonio ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Colorectal cancer; EGF receptor; Monoclonal antibodies; Panitumumab

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; IMMUNOGLOBULIN G2; IRINOTECAN; K RAS PROTEIN; LOPERAMIDE; MAGNESIUM; OXALIPLATIN; PANITUMUMAB;

ACNE; CANCER PATIENT; CHEILITIS; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE TOXICITY; FATIGUE; HAIR DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; INTERMETHOD COMPARISON; LUNG EMBOLISM; MONOTHERAPY; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PROGRESSION FREE SURVIVAL; REVIEW; SKIN FISSURE; SKIN MANIFESTATION; SKIN PRURITUS; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EXANTHEMA; GENE DOSAGE; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 77249159315     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.06.005     Document Type: Review

References (47)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of care incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic region of the world. J Clin Oncol 26 (2006) 2137-2150
2. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
3. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355 (2000) 1041-1047
4. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
5. Capdevila J., Saura C., Macarulla T., et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 33 Suppl 2 (2007) S24-S34
6. Salomon D.S., Brandt R., Ciardello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 3 (1995) 183-232
7. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001) 2958-2970
8. http://www.emea.europa.eu/humandocs/Humans/EPAR/erbitux/erbitux.htm
9. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Oncol Hematol 38 (2001) 17-23
10. Foon K.A., Yang X.D., Weiner L.M., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 (2004) 984-990
11. Yang X.D., Jia X.C., Corvalan J.R., et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59 (1999) 1236-1243
12. Freeman D., McDorman K., Bush T., et al. Mono- and combination-therapeutic activity of panitumumab on human A431 epidermoid and HT-29 colon carcinomas xenografts: correlation with pharmacodynamic parameters. Eur J Cancer Suppl (2004) Abstr 95
13. http://www.emea.europa.eu/humandocs/Humans/EPAR/vectibix/vectibix.htm
14. Weiner L.M., Belldegrun A.S., Crawford J., et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14 (2008) 502-508
15. Stephenson JJ, Cohn A, Crawford J, et al. Administration of panitumumab (Pmab) every two weeks (Q2W) as a 30-min or 60-min infusion: safety and pharmacokinetics (PK) from a phase 1 study in patients with solid tumors. Gastrointestinal Cancers Symposium, Orlando, 2007; Abstr. 368.
16. Wainberg Z.A., and Hecht J.R. Panitumumab in colorectal cancer. Expert Rev Anticancer Ther 7 (2007) 967-973
17. ®. http://www.emea.europa.eu/humandocs/Humans/EPAR/vectibix/vectibix.htm. Accessed on March 31, 2008.
18. Hecht J.R., Patnaik A., Berlin J., et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110 (2007) 980-987
19. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mmCRC) expressing ≥ 10% epidermal growth factor receptor (EGFR). American Society of Clinical Oncology, Orlando, 2006; Abstr. 3548.
20. Hecht R, Mitchell EP, Baranda J, et al. Panitumumab (Pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 343.
21. Yoshino T, Muro K, Doi T, et al. Phase 2 study of Panitumumab (Pmab) monotherapy in Japanese patients (pts) with metastatic colorectal cancer (mCRC) after the failure of fluoropyrimidine, irinotecan (CPT-11) and oxaliplatin (OHP) chemotherapy. Gastrointestinal Cancers Symposium, Orlando, 2008; Abstr. 366.
22. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
23. Van Cutsem E., Siena S., Humblet Y., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19 (2008) 92-98
24. Berlin J., Posey J., Tchekmedyian S., et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 6 (2007) 427-432
25. Siena S., Tabernero J., Burkes R.L., et al. Phase III study (PRIME/200505203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. J Clin Oncol 26 (2008) Abstr. 4034
26. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 (2008) 672-680
27. Tol J., Koopman M., Rodenburg C.J., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19 4 (2008) 734-738
28. Peeters M, Wilson G, Ducreux M, et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. American Society of Clinical Oncology, Chicago, 2008; Abstr. 4064.
29. nd-line treatment (tx): Interim analysis. American Society of Clinical Oncology, Chicago, 2008; Abstr. 15007.
30. Mitchell EP, LaCouture ME, Shearer H, et al. A phase II, open-label, randomized clinical trial of skin toxicity evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving 2nd line FOLFIRI or irinotecan-only chemotherapy (CT) with panitumumab (pmab): Early analysis. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 462.
31. Asmis TR, Shah MA, Haviland D, Kemeny N. Panitumumab with or without chemotherapy in metastatic colorectal cancer (mCRC): Safety and unusual activity, even following progression on cetuximab. Gastrointestinal Cancers Symposium, Orlando, 2008; Abstr. 484.
32. Peeters M, Van Cutsem E, Berlin J, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. American Society of Clinical Oncology, Chicago, 2007; Abstr. 4138.
33. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
34. Hecht R, Mitchell EP, Baranda J, et al. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 343.
35. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 (2008) 508-515
36. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 (2007) 1166-1169
37. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (2007) 2643-2648
38. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237
39. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Eng J Med 359 (2008) 1757-1765
40. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008) 5705-5712
41. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
42. Sartore-Bianchi A., Moroni M., Veronese S., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25 (2007) 3228-3245
43. Humblet Y, Peeters M, Siena S, et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, 2007; Abstr. 4038.
44. Michelini T, Hecht JR, Peeters M, et al. Pooled analysis of five clinical trials examining the predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC). American Society of Health-System Pharmacists, Las Vegas, 2007; P141D.
45. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Eng J Med 357 20 (2007) 2040-2048
46. Van Cutsen E., Kohne C.-H., Hitre E.H., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009) 1408-1417
47. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, Leucovorin and Oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (2009) 663-671